Avsnittsbeskrivning
The FDA has drawn a new line in the sand for medical device cybersecurity. Since March 2024, the "Refuse to Accept" policy is in full effect, turning premarket submissions into a high-risk gamble for unprepared manufacturers. In this episode, we dissect the immediate fallout and what companies are experiencing right now.
We explore how a missing Software Bill of Materials (SBOM) or a weak post-market surveillance plan can halt your U.S. market access indefinitely. Imagine spending millions to develop a groundbreaking connected device, only to have the FDA reject your submission based on a…
Webbplats: pureglobal.com

